SOTAC PHARMACEUTICALS
|
SOTAC PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 3.87 | 3.58 | 12.52 | -10.28 | 0.38 |
| CEPS(Rs) | 6.05 | 5.67 | 4.98 | 0.28 | 1.85 |
| DPS(Rs) | - | - | 2.00 | - | - |
| Book NAV/Share(Rs) | 40.96 | 12.41 | 28.79 | 10.84 | 13.29 |
| Tax Rate(%) | 9.70 | 41.78 | 38.68 | -15.02 | 75.49 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 8.23 | 9.44 | 8.44 | 2.98 | 6.53 |
| EBIT Margin(%) | 5.49 | 7.70 | 7.20 | -2.11 | 2.41 |
| Pre Tax Margin(%) | 3.82 | 5.07 | 6.42 | -4.21 | 1.25 |
| PAT Margin (%) | 3.45 | 2.95 | 3.94 | -4.84 | 0.31 |
| Cash Profit Margin (%) | 6.43 | 5.89 | 5.48 | 0.47 | 5.20 |
| Performance Ratios | |||||
| ROA(%) | 4.03 | 4.20 | 8.23 | -7.27 | 0.29 |
| ROE(%) | 12.96 | 27.53 | 63.16 | -85.23 | 2.86 |
| ROCE(%) | 10.22 | 21.50 | 31.31 | -5.71 | 4.18 |
| Asset Turnover(x) | 1.17 | 1.42 | 2.09 | 1.50 | 0.94 |
| Sales/Fixed Asset(x) | 2.65 | 3.34 | 4.12 | 2.39 | 1.52 |
| Working Capital/Sales(x) | 6.14 | 58.39 | -42.31 | -9.02 | -5.11 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.38 | 0.30 | 0.24 | 0.42 | 0.66 |
| Receivable days | 72.11 | 63.58 | 45.25 | 47.99 | 88.82 |
| Inventory Days | 55.63 | 44.84 | 25.51 | 26.72 | 29.65 |
| Payable days | 124.45 | 143.83 | 106.65 | 112.91 | 193.78 |
| Valuation Parameters | |||||
| PER(x) | 31.23 | - | - | - | - |
| PCE(x) | 20.02 | - | - | - | - |
| Price/Book(x) | 2.95 | - | - | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.49 | 0.26 | 0.13 | 0.39 | 0.54 |
| EV/Core EBITDA(x) | 17.17 | 2.66 | 1.51 | 12.26 | 7.33 |
| EV/EBIT(x) | 27.21 | 3.42 | 1.83 | -18.58 | 22.20 |
| EV/CE(x) | 2.21 | 0.49 | 0.27 | 0.55 | 0.50 |
| M Cap / Sales | 1.29 | - | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 34.00 | 5.92 | 49.77 | 70.76 | - |
| Core EBITDA Growth(%) | 17.87 | 19.94 | 309.00 | -25.23 | - |
| EBIT Growth(%) | -4.46 | 13.37 | 610.65 | -249.43 | - |
| PAT Growth(%) | 56.57 | -20.58 | 221.70 | -2,803.31 | - |
| EPS Growth(%) | 8.32 | -71.42 | 221.70 | -2,803.31 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.55 | 2.21 | 1.12 | 6.87 | 4.40 |
| Current Ratio(x) | 1.39 | 1.03 | 0.94 | 0.76 | 0.71 |
| Quick Ratio(x) | 0.97 | 0.73 | 0.74 | 0.55 | 0.59 |
| Interest Cover(x) | 3.28 | 2.92 | 9.24 | -1.01 | 2.07 |
| Total Debt/Mcap(x) | 0.19 | - | - | - | - |
Compare Financial Ratios of peers of SOTAC PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SOTAC PHARMACEUTICALS | ₹119.9 Cr | -2.7% | -13.9% | -19.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,936.0 Cr | -5.8% | -3.2% | 35.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹152,157.0 Cr | -2.8% | -3.6% | 44.7% | Stock Analytics | |
| CIPLA | ₹116,200.0 Cr | -3.9% | -0.5% | 13.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,325.0 Cr | -1.2% | 7.1% | 17.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,037.4 Cr | -2.7% | -0.1% | 40.9% | Stock Analytics | |
SOTAC PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SOTAC PHARMACEUTICALS | -2.7% |
-13.9% |
-19.6% |
| SENSEX | -2.1% |
-6.4% |
7% |
You may also like the below Video Courses
